Blog
Pharma, Heal Thyself On Drug Pricing
Pharma needs to boost its credibility on drug pricing. How about renouncing huge yearly price hikes?
What Is Theranos's Business Model, Anyway?
There are plenty of ways to win in diagnostics - Theranos just needs to pick one.
Can Businesses Learn 'Superforecasting'? Easier Said Than Done
Business leaders should read Philip Tetlock's new book on analyzing data to predict the future - but whether they'll be able to implement its ideas is far from certain.
Pharma CEOs Should Take A Stand On Egregious Price Increase -- But They Won't
Pharma CEOs have the chance to take the "high ground" on drug pricing in the Turing brouhaha. I'm not holding my breath.
Technology, end-of-life care, and 'Being Mortal'
Atul Gawande's recent book on end-of-life care is inspiring and thought-provoking - and an important must-read for tech experts, entrepreneurs, and investors.
Biotech's R&D Talent Opportunity
Mid-level "leader-doers" make the magic happen in R&D. Here's how to get them.
Pharma's hunt for academic innovation
Pharma overlooks many potentially valuable collaborations by focusing exclusively on the academic "A-list".
Enabling R&D collaborations between academia and pharma
Many academic researchers aren't aware of opportunities to collaborate with pharma R&D organizations - so we created a directory to help them. Check it out!
The case for "biotech paranoia"
Biotechs need to get anxious - really anxious - about how changes in the industry will affect Pharma deal-making.
Drug pricing is the new Big Pharma giant-killer
Is the new contracting deal in hepatitis C a meaningless blip, or the “end of days” for biopharma? (Spoiler alert: "no” and “no”.)